Navigation Links
Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015
Date:8/22/2011

FRAZER, Pa., Aug. 22, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today provided notice to holders of its 2.50 percent Convertible Senior Subordinated Notes due 2014 (the "2014 Notes") and 2.00 percent Convertible Senior Subordinated Notes due 2015 (the "2015 Notes") in respect of the Merger (as defined below) of the Company with a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., an Israeli corporation ("Parent"), the consummation of which will constitute a Fundamental Change under each of the Indenture governing the 2014 Notes (the "2014 Indenture") and the Indenture governing the 2015 Notes (the "2015 Indenture").  The 2014 Notes will be convertible in connection with the Merger at the option of the holders on the effective date of the Merger and will remain convertible until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding the Fundamental Change Purchase Date (as defined in the 2014 Indenture) relating to such Fundamental Change (such period, the "2014 Applicable Conversion Period").  The 2015 Notes will be convertible in connection with the Merger at the option of the holders at any time beginning 40 days before the anticipated effective date of the Merger and will remain convertible until 5:00 p.m., New York City time, on the second trading day immediately preceding the Fundamental Change Purchase Date (as defined in the 2015 Indenture) relating to such Fundamental Change (such period, the "2015 Applicable Conversion Period").  

If consummated, the Merger will additionally constitute a Make-Whole Adjustment Event under Section 4.02 of the 2014 Indenture, which will entitle holders converting their 2014 Notes during the 2014 Applicable Conversion Period to convert such 2014 Notes at an increased conversion rate based on the table set forth in Section 4.02 of the 2014 Indenture.  
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ
2. Cephalon Shareholders Approve Acquisition by Teva
3. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
4. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
5. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
6. Cephalon Lodges Bidders Statement for A$167 Million Offer for ChemGenex Pharmaceuticals
7. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
8. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
9. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
10. Cephalon Wins FENTORA Patent Suit Against Watson
11. Cephalon Announces Definitive Agreement to Acquire Gemin X
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... THOUSAND OAKS, Calif. and LONDON ... AMGN ) and AstraZeneca (NYSE: AZN ) today ... trial evaluating two doses of brodalumab in more than 1,800 ... compared with both Stelara ® (ustekinumab) and placebo at ... the brodalumab weight-based analysis group were each shown to be ...
(Date:11/26/2014)... SAN DIEGO , Nov. 25, 2014 Halozyme ... at the Piper Jaffray Healthcare Conference in New ... p.m. EDT/10:00 a.m. PDT . Dr. Helen Torley ... overview. The presentation will be webcast through the ... and a recording will be made available for 90 days ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... the Study of the ... Liver Annual Meeting -, SAN FRANCISCO, April ... 2 study of its lead,compound, MitoQ(R) (mitoquinone) in liver disease. The results ... of the Liver,(EASL) Annual Meeting, being held April 23 - 27 in ...
... at the 10th Annual Superbugs and Superdrugs Conference on ... ... Mass., April 10 Enanta Pharmaceuticals, a,leader in the development ... breakthrough research program to,evaluate a new macrolide-related drug class, Bicyclolides, ...
Cached Medicine Technology:Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R) 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 3
(Date:11/26/2014)... Dr. Rod J. Rohrich, Dallas ... the Department of Plastic Surgery at UT Southwestern ... grafting, and modern lift-and-fill facelifts before colleagues at ... by the American Society of Plastic Surgeons (ASPS). ... structure were explored in detail during Dr. Rohrich's ...
(Date:11/26/2014)... By Amy Norton ... -- While people have long believed their dogs understand what ... meaning and emotion of words in a human-like way. ... of human speech -- including the actual content and the ... team,s findings give a deeper insight into the canine brain, ...
(Date:11/26/2014)... Nov. 26, 2014 (HealthDay News) -- More than half ... their thinking and memory skills, a new study suggests. ... Neurology , "approximately 1.8 million Americans over the age ... of their cognitive [mental] abilities," study author Dr. Vikas ... Ann Arbor, said in a journal news release. ...
(Date:11/26/2014)... Deptford, NJ (PRWEB) November 26, 2014 ... and Lourdes Cardiology have launched a partnership designed ... readmission rates for congestive heart failure (CHF) patients ... Deptford Center staff and Lourdes Cardiology team will ... developed and supervised protocols. This partnership pairs the ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used ... that looks and acts similar to asbestos-induced mesothelioma. Surviving ... research. Click here to read it now. ... Experimental Medicine in Hannover injected 500 lab rats with ... eventually developed mesothelioma , how quickly it developed ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 3Health News:Your Dog Really Is Listening to You 2Health News:Your Dog Really Is Listening to You 3Health News:Too Few Americans Undergo Dementia Screening 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2
... , , NASHVILLE, ... $11.6 and $18 billion in diagnostic imaging costs over the ... program similar to those used in the private sector. Currently, ... billions of dollars. According to an independent analysis released today ...
... , , , ... , , FAIRFAX, Va., July 16 ... a cancer survivor in the Chicago area who has dedicated his or ... winner of the Survivor Circle Award will receive $1,000 and be honored ...
... , The hospital is the highest-rated Illinois ... , CHICAGO, July 16 Northwestern Memorial Hospital is ... ranked in Illinois -- as part of U.S. News & World Report,s 2009 ... guide evaluated 4,861 medical centers nationwide and 174 were chosen and ranked according ...
... get LASIK, researchers say , THURSDAY, July 16 (HealthDay ... surgery may benefit from implantable lenses made of a ... LASIK "has gained widespread popularity as a safe and ... with high [severe] myopia or thin corneas face some ...
... , , , ... www.STDTestExpress.com ) offers leading direct-to-consumer testing services for sexually ... on the Internet to have partnered with a telemedicine network ... to order these specialty tests, discuss STD symptoms, review test ...
... 16 Enigma Diagnostics Limited, the decentralized and point-of-care molecular ... license agreements with Roche Molecular Systems, Inc. (RMS). , ... July 2009, provide Enigma full access under patents owned or ... PCR chemistry and melt analysis and will allow Enigma to ...
Cached Medicine News:Health News:Radiology Benefit Management Could Save Medicare up to $18 Billion Over 10 Years 2Health News:Radiology Benefit Management Could Save Medicare up to $18 Billion Over 10 Years 3Health News:Award Honors Chicago Cancer Survivor Who Gives Back 2Health News:Award Honors Chicago Cancer Survivor Who Gives Back 3Health News:Award Honors Chicago Cancer Survivor Who Gives Back 4Health News:Northwestern Memorial Among America's Best Hospitals in 11 Clinical Specialties According to U.S. News' 2009 Rankings 2Health News:Northwestern Memorial Among America's Best Hospitals in 11 Clinical Specialties According to U.S. News' 2009 Rankings 3Health News:New Option for Correcting Nearsightedness 2Health News:STD Test Express Offers Free Doctor Consultations With Every STD Test 2Health News:Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc. 2
Shandon Slide File Storage System...
Shandon Plastic Slide Folders...
Shandon Microscope Slide Cabinet with Drawers...
... containing over 330 species of microorganisms ... Compact offers enhanced identification capabilities. In ... to 14 hours), it identifies the ... production areas and final products., Therefore, ...
Medicine Products: